[Pharmacokinetics and clinical effects of XXXX fine granules in pediatrics].

@entity1 @entity3617 @entity7551 @entity294 @entity2348 @entity5389 @entity281 @entity869 @entity7576 @entity5899 @entity2335 @entity293
We have evaluated @entity7576 (SBTPC) fine granules for pharmacokinetics and therapeutic effectiveness in @entity1 . The results are summarized as follows. 1. Pharmacokinetic parameters after the oral administration of single dose of 5.0 mg per kg body weight in 1 @entity1 were as follows: The peak serum concentrations of @entity869 (ABPC) and @entity5899 (SBT) were 1.92 micrograms/ml at 1 hour and 1.85 micrograms/ml at 1 hour, respectively. The half-lives in serum and urinary excretion rate for ABPC and SBT were similar. 2. A clinical study was performed on 15 @entity1 with @entity281 , including 4 with @entity5389 , 5 with @entity7551 , 2 each with @entity3617 , @entity2335 , and @entity293 . Doses ranging from 6.7 to 18.2 mg/kg body weight were given tid. or qid. Lengths of treatment ranged from 5 to 10 days. The therapeutic responses were considered "excellent" in 6 and "good" in 9, with an effectiveness rate of 100%. 3. As to side effects of the drug, @entity294 was observed in 1 @entity1 . It was concluded that SBTPC was a promising drug for the treatment of @entity2348 in @entity1 .
